Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk

TAN Yue; DI Weinan

Abstract：Objective To observe the effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Meth-ods 135 outpatients with chronic kidney disease were randomly divided into the treatment group and the control group. Patients in the treatment group were treated with allopurinol. Antihypertensive drugs, lipid-lowering agents and antiplatelet drugs maintained the origi-nal constant dose. Patients in the control group continued to receive the usual therapy. Respective observation was made of the changes in blood pressure, blood uric acid, hypersensitive c-reactive protein, bladder inhibition-C and glomerular filtration rate (eGFR) in the two groups of patients in a 6, 12 and 24 months. The incidence of patients’ cardiovascular events got recorded during treatment. Results There is no difference in the general data of the two groups of patients. After treatment of 6 , 12 and 24 months, the hs CRP, blood uric acid concentration as well as inhibition-C concentration in the treatment group were significantly lower than before (P<0. 05). Comparison within groups was also significantly lower than the control group (P<0. 05). eGFR of the treatment group in the follow-up for 12 months and 24 months was significantly higher than that of the control group (P<0. 05). Allopurinol can reduce the risk of cardiovascular events by 71% compared with normal therapy. (P= 0. 026). Conclusion Allopurinol can reduce the inflam-matory response and slow down the progression of renal disease in patients with chronic kidney disease. In addition, allopurinol can re-duce cardiovascular risk in these subjects.